Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 51

Drug Profile

IC 51

Alternative Names: IC-51; Ixiaro; Japanese-encephalitis-purified-inactivated-vaccine-Valneva; Japanese-encephalitis-vaccine-Intercell; JE-PIV; JE-PIV-Valneva; Jeev; Jespect; JEV-vaccine-Intercell; JEV-vaccine-Valneva; Jeval

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VaccGen International LLC
  • Developer Adimmune Corporation; Biological E Limited; CSL; Valneva
  • Class Attenuated vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Japanese encephalitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Japanese encephalitis

Most Recent Events

  • 09 Sep 2020 IC 51 licensed to the US Government Department of Defense in USA for prevention against Japanese encephalitis
  • 01 Sep 2020 Registered for Japanese encephalitis (In infants, In children, In adolescents, Prevention) in Japan (IM) before September 2020
  • 01 Sep 2020 Registered for Japanese encephalitis (In infants, In children, In adolescents, Prevention) in South Korea (IM) before September 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top